Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. - Test2 - elhamkhani - TriplyDB

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

http://www.wikidata.org/entity/Q37584395

about

CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation.

P2860

Q41076029-3A3935DE-C6F9-4078-BFC0-D4DAC86BEC20

P2860

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

http://www.wikidata.org/entity/Q37584395

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Are immune checkpoint blockade ...... dence and future perspectives.

@en

Are immune checkpoint blockade ...... dence and future perspectives.

@nl

type

label

Are immune checkpoint blockade ...... dence and future perspectives.

@en

Are immune checkpoint blockade ...... dence and future perspectives.

@nl

prefLabel

Are immune checkpoint blockade ...... dence and future perspectives.

@en

Are immune checkpoint blockade ...... dence and future perspectives.

@nl

P1433

Q37584395-60C6F4FF-820F-4BD9-A1A1-7CA81254145F

P1476

Q37584395-25D264AC-6C00-42DE-AD3E-5A8BF9E2ABBC

P2093

Q37584395-49086CA9-19BD-4903-979F-E4B559DF8F4D

Q37584395-7A0286EE-9C88-47C0-B84F-36DC4EAA0F42

P2860

Q37584395-001CE855-0EB5-4F22-8C49-397578558BFA

Q37584395-00A93F42-2079-4A07-8187-A109DEAA79A0

Q37584395-06581CA1-A79C-4562-87B0-BB3E9D66B441

Q37584395-086FC009-CFCF-4671-8FDE-D95F28386C42

Q37584395-08E0D674-A593-49C1-8DE6-853615E3AB63

Q37584395-0DC3F085-ED3C-4A1B-A0EA-F085BB30469C

Q37584395-12E9875A-D667-4BB1-9496-5793A0939F83

Q37584395-1A65C04A-756B-4314-A047-BB63713900A1

Q37584395-28EF3DE8-EF90-43C0-AFBC-D435223C5000

Q37584395-2F000BC1-1881-4E9F-BC1D-222794FA7B1A

P304

Q37584395-DAE584A4-C514-481C-8546-B2ED66BF28AD

P31

Q37584395-F194A696-D976-489F-B6E3-A1007086A31C

P356

Q37584395-C5FD76E3-B0F8-4373-9079-481251DCC6EF

P433

Q37584395-26F57D70-53F9-4D7C-A2F4-7407088E5579

P478

Q37584395-E9FD1438-E4F7-4F58-B6BB-15981A7E28F2

P577

Q37584395-9930BBFF-D3BB-4A0E-8059-4AB0E1FC2FD6

P698

Q37584395-5DD55E24-56D3-4526-9102-3F3D28AED53A

P932

Q37584395-77FE0DB9-5200-4CA4-9290-F618736DF3AF

P356

TLCR.2016.09.05

P1433

Translational lung cancer research

P1476

Are immune checkpoint blockade ...... dence and future perspectives.

@en

P2093

Grainne M O'Kane

http://www.w3.org/2001/XMLSchema#string

Natasha B Leighl

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Systemic Immunotherapy for the Treatment of Brain Metastases

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules

Structural and functional features of central nervous system lymphatic vessels.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

P304

628-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TLCR.2016.09.05

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28149757

http://www.w3.org/2001/XMLSchema#string

P932

5233870

http://www.w3.org/2001/XMLSchema#string